Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera-Reference-Cited by-同舟云学术

Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera

Published:2014-09 Issue: Volume:14 Page:S36-S41
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Alchalby Haefaa,Kröger Nicolaus

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference56 articles.

1. Pathogenesis of myelofibrosis with myeloid metaplasia;Tefferi;J Clin Oncol,2005

2. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

3. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

4. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment);Passamonti;Blood,2010

5. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients;Caramazza;Leukemia,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis;European Journal of Haematology;2018-07-04

2. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study;Haematologica;2017-12-07

3. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T;Current Hematologic Malignancy Reports;2016-09-24

4. Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations;Journal of Blood Medicine;2016-09

5. Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis;Current Hematologic Malignancy Reports;2015-08-16